C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells
A new editorial perspective titled "C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells" has been published in Oncotarget.
Nov 13, 2023
0
0
A new editorial perspective titled "C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells" has been published in Oncotarget.
Nov 13, 2023
0
0
A novel assay that detects a unique molecular marker in patients with acute myeloid leukemia (AML) may revolutionize the way this disease is detected and treated according to a new report in The Journal of Molecular Diagnostics. ...
Nov 13, 2023
0
0
A new editorial paper was published in Oncotarget, titled "Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors."
Nov 8, 2023
0
0
A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James), may offer a new treatment option ...
Nov 6, 2023
0
37
A discovery by a QIMR Berghofer-led team of international scientists has potentially unlocked an entirely new approach to targeting the blood cancer acute myeloid leukemia, bringing hope to patients who are no longer responding ...
Oct 30, 2023
0
40
Children with Down syndrome have an increased risk of developing acute lymphoblastic leukemia (ALL) and experience higher rates of relapse and treatment toxicity. In recent decades, new therapies have improved outcomes for ...
Oct 30, 2023
0
0
The unique signaling protein known as TRPM7 can stimulate and interact with an important cellular signaling hub called the AKT machinery, which is a well-known component of multiple cellular functions that drive growth and ...
Oct 26, 2023
0
0
Selenium-enriched diets may help ward off myeloid leukemia, and a new study led by researchers in Penn State's College of Agricultural Sciences has described the mechanism by which this occurs.
Oct 24, 2023
0
66
There is a clear, unmet need for tolerable treatments that can produce durable remission among patients with higher-risk myelodysplastic syndromes (HR-MDS), according to a study published online Sept. 7 in Leukemia & Lymphoma.
Oct 20, 2023
0
0
Researchers have revealed a new mechanism of targeted drug treatment used against chronic lymphocytic leukemia, through the promotion of immune cell function, that could be exploited using new anti-cancer immunotherapies.
Oct 19, 2023
0
0